Wilhelmina C. M. Duivenvoorden

Wilhelmina C. M. Duivenvoorden

Auto-generated profile, based on publicly available information

Wilhelmina C. M. Duivenvoorden

Department of Surgery, Division of Urology, McMaster University, Hamilton, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2021 in The Prostate
Verified
Journal Article
Open access
PDF file
TYTohru Yoneyama
Tohru Yoneyama
HYHayato Yamamoto
Hayato Yamamoto
MYMihoko Sutoh Yoneyama
Mihoko Sutoh Yoneyama
YTYuki Tobisawa
Yuki Tobisawa
SHShingo Hatakeyama
Shingo Hatakeyama
COChikara Ohyama
Chikara Ohyama
Background: The presence of glycosylated isoforms of prostate‐specific antigen (PSA) in prostate cancer (PC) cells is a potential marker of their aggressiveness. We characterized the origin of α2,3‐sialylated prostate‐specific antigen (S23PSA) by tissue‐based sialylation‐related gene expression and studied the performance of S23PSA density (S23PSAD) alone and in combination with multiparametric magnetic resonance imaging (MRI) for the detection of clinically significant prostate cancer in men with elevated PSA.Methods: Tissue‐based quantification of S23PSA and sialyltransferase and sialidase gene expression was evaluated in 71 radical prostatectomy specimens. The diagnostic performance of S23PSAD was studied in 1099 men retrospectively enrolled in a multicenter systematic biopsy (SBx) cohort. We correlated the S23PSAD with Prostate Imaging Reporting and Data System (PI‐RADS) scores in 98 men prospectively enrolled in a single‐center MRI‐targeted biopsy (MRI–TBx) cohort. The primary outcome was the PC‐diagnostic performance of the S23PSAD, the secondary outcome was the avoidable biopsy rate of S23PSAD combined with DRE and total PSA (tPSA), and with or without PI‐RADS.Results: S23PSA was significantly higher in Gleason pattern 4 and 5 compared with benign prostate tissue. In the retrospective cohort, the performance of S23PSAD for detecting PC was superior to tPSA or PSA density (PSAD) (AUC: 0.7758 vs. 0.6360 and 0.7509, respectively). In the prospective cohort, S23PSAD was superior to tPSA, PSAD, and PI‐RADS (AUC: 0.7725 vs. 0.5901, 0.7439 and 0.7305, respectively), and S23PSAD + PI‐RADS + DRE + tPSA was superior to DRE + tPSA+PI‐RADS with avoidance rate of MRI–TBx (13% vs. 1%) at 30% risk threshold.Conclusions: The diagnostic performance of S23PSAD was superior to conventional strategies but comparable to mpMRI.

6 November 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
JMJoseph Moryousef
Joseph Moryousef
WDWilhelmina Duivenvoorden
Wilhelmina Duivenvoorden
DLDarryl Leong
Darryl Leong
JPJehonathan H. Pinthus
Jehonathan H. Pinthus

25 April 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
JPJehonathan H. Pinthus
Jehonathan H. Pinthus
WDWilhelmina C. M. Duivenvoorden
Wilhelmina C. M. Duivenvoorden

28 September 2020 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
WDWilhelmina C. M. Duivenvoorden
Wilhelmina C. M. Duivenvoorden
MNMagda Naeim
Magda Naeim
SHSarah N. Hopmans
Sarah N. Hopmans
SYSadiya Yousef
Sadiya Yousef
GWGeoff H. Werstuck
Geoff H. Werstuck
JPJehonathan H. Pinthus
Jehonathan H. Pinthus

15 March 2019 in European Urology Supplements
Verified
Journal Article
Closed access
PDF file
TYTohru Yoneyama
Tohru Yoneyama
YTYuki Tobisawa
Yuki Tobisawa
TKT. Kaneko
T. Kaneko
TKT. Kaya
T. Kaya
SHShingo Hatakeyama
Shingo Hatakeyama
COC. Ohyama
C. Ohyama

19 August 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
WDWilhelmina C. M. Duivenvoorden
Wilhelmina C. M. Duivenvoorden
MNMagda Naeim
Magda Naeim
SHSarah N. Hopmans
Sarah N. Hopmans
SYSadiya Yousef
Sadiya Yousef
GWGeoff H. Werstuck
Geoff H. Werstuck
JPJehonathan H. Pinthus
Jehonathan H. Pinthus